RxDoctor Payments DataLook up a doctor →

Sandip Jain, MD

Neurology · Greenville, SCNPI 1750456869

Payments from drug & device makers

$42,809in general payments, 2019–2025

Across 513 payments — averaging $83.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$22K
  • Argenx US, Inc.$10K
  • Novartis$2K
  • EDW Pharma, Inc.$2K
  • AbbVie$826
  • Neurocrine Biosciences, Inc.$631
  • plus $6K from 46 others

What the payments were for

  • Consulting fees$19,98847%
  • Speaking & faculty fees$7,72818%
  • Travel & lodging$2,8607%
  • Food & beverage$10,83325%
  • Education$4471%
  • Gifts$9532%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$42,809 in reported general payments places this provider in the 85th percentile of 270 neurology providers in South Carolina.

See all neurology providers in South Carolina

Medicare billing

Part B allowed, 2024
$120,888
Medicare patients
468
Services billed
1,598

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 4683$448,882
EvrysdiRisdiplam13$343,440
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5017$314,278
GammakedImmune Globul G/Gly/Iga Avg 4630$183,447
Kesimpta PenOfatumumab15$152,261
XembifyImmune Globulin,gamma(Igg)klhw12$95,083
NuplazidPimavanserin Tartrate14$71,138
Glatiramer Acetate14$37,632
Aimovig AutoinjectorErenumab-Aooe49$37,299
UbrelvyUbrogepant18$37,167
Emgality PenGalcanezumab-Gnlm27$22,425
Dalfampridine ErDalfampridine33$14,799
KeppraLevetiracetam12$13,655
Dimethyl Fumarate33$8,545
Carbidopa-LevodopaCarbidopa/Levodopa92$6,590

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCGamunex-C, Xembify$128$543,96595 claims
Genentech USA, Inc.Evrysdi$201$343,44013 claims
CSL BehringPrivigen$192$314,27817 claims
Acadia Pharmaceuticals IncNuplazid$236$71,13814 claims
AbbVieUbrelvy$826$37,16718 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil$42$8,03979 claims
Upsher-smith Laboratories LLCTopiramate$32$62057 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 270 neurology providers in South Carolina.

Other neurology in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →